Intech Biopharm Corporation (TPEX:6461)

Market Cap	2.68B -8.6%
Revenue (ttm)	48.55M -57.9%
Net Income	-482.02M
EPS	-4.60
Shares Out	110.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,784
Open	24.00
Previous Close	24.30
Day's Range	24.00 - 24.50
52-Week Range	22.79 - 42.44
Beta	0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 96
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2025, Intech Biopharm's revenue was 107.53 million, an increase of 170.31% compared to the previous year's 39.78 million. Losses were -389.03 million, 5.66% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error